urapidil has been researched along with Obesity in 1 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flechtner-Mors, M | 1 |
| Jenkinson, CP | 1 |
| Alt, A | 1 |
| Adler, G | 1 |
| Ditschuneit, HH | 1 |
1 trial available for urapidil and Obesity
| Article | Year |
|---|---|
In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects.
Topics: Adipose Tissue; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adren | 2002 |